Genentech's EVP of research and early development Aviv Regev at #JPM23 (Adrien Villez for Endpoints News)

Ex­clu­sive: Aviv Regev talks three years of lead­ing Genen­tech’s re­search, the fu­ture of AI, and not mak­ing No­bel pre­dic­tions

SOUTH SAN FRAN­CIS­CO — In 2020, Aviv Regev end­ed an es­teemed 14-year run at the Broad In­sti­tute to jump in­to the drug in­dus­try, be­com­ing Genen­tech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.